Your browser is no longer supported. Please, upgrade your browser.
Settings
AGIO Agios Pharmaceuticals, Inc. daily Stock Chart
AGIO [NASD]
Agios Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-6.31 Insider Own8.50% Shs Outstand47.78M Perf Week2.70%
Market Cap3.19B Forward P/E- EPS next Y-7.35 Insider Trans13.72% Shs Float41.73M Perf Month21.81%
Income-268.60M PEG- EPS next Q-1.79 Inst Own- Short Float16.15% Perf Quarter29.17%
Sales53.50M P/S59.71 EPS this Y-61.30% Inst Trans14.60% Short Ratio13.07 Perf Half Y19.05%
Book/sh10.89 P/B6.14 EPS next Y-4.00% ROA-41.20% Target Price74.11 Perf Year43.41%
Cash/sh12.26 P/C5.45 EPS next 5Y- ROE-68.10% 52W Range39.24 - 67.74 Perf YTD60.22%
Dividend- P/FCF- EPS past 5Y10.60% ROI-56.00% 52W High-1.30% Beta1.94
Dividend %- Quick Ratio6.50 Sales past 5Y26.20% Gross Margin- 52W Low70.38% ATR1.95
Employees287 Current Ratio6.50 Sales Q/Q61.40% Oper. Margin- RSI (14)68.32 Volatility2.34% 3.27%
OptionableYes Debt/Eq0.00 EPS Q/Q-20.60% Profit Margin- Rel Volume0.99 Prev Close66.86
ShortableYes LT Debt/Eq0.00 EarningsAug 08 BMO Payout- Avg Volume515.64K Price66.86
Recom1.90 SMA208.11% SMA5012.40% SMA20028.74% Volume0 Change0.00%
Sep-15-17Initiated RBC Capital Mkts Outperform $78
Aug-10-17Reiterated Needham Buy $54 → $72
Aug-08-17Reiterated SunTrust Buy $68 → $80
Aug-02-17Upgrade Leerink Partners Mkt Perform → Outperform $80
Jun-26-17Downgrade Janney Buy → Neutral
Jan-17-17Upgrade Oppenheimer Perform → Outperform
Oct-24-16Initiated Needham Buy $60
Jun-13-16Upgrade JP Morgan Neutral → Overweight
May-18-16Reiterated SunTrust Buy $57 → $65
May-18-16Reiterated Sun Trust Rbsn Humphrey Buy $57 → $65
Mar-30-16Initiated Sun Trust Rbsn Humphrey Buy $57
Jan-21-16Initiated Credit Suisse Outperform
Dec-07-15Downgrade Leerink Partners Outperform → Mkt Perform
Nov-09-15Reiterated ROTH Capital Neutral $114 → $75
Jul-22-15Initiated Northland Capital Outperform $132
Jun-15-15Reiterated Canaccord Genuity Hold $103 → $93
Apr-21-15Initiated Oppenheimer Perform
Feb-18-15Reiterated MLV & Co Buy $123 → $130
Jan-05-15Initiated ROTH Capital Neutral
Dec-04-14Initiated MLV & Co Buy $123
Sep-18-17 05:22PM  ETFs with exposure to Agios Pharmaceuticals, Inc. : September 18, 2017 Capital Cube
Sep-12-17 08:01AM  See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc. Markit
Sep-07-17 01:29PM  Jazz Pharmaceuticals on the Street: Analysts Recommendations after 1H17 Market Realist
12:15PM  ETFs with exposure to Agios Pharmaceuticals, Inc. : September 7, 2017 Capital Cube
Sep-06-17 08:47AM  Agios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: Q2, 2017 By the Numbers : September 6, 2017 Capital Cube
Sep-05-17 07:30AM  Agios to Present at the Morgan Stanley 15th Annual Global Healthcare Conference Monday, September 11, 2017 GlobeNewswire
Sep-01-17 12:08PM  5 of the Most Hated Biotech Stocks on the Market: Are They Buys? Motley Fool
Aug-31-17 08:07AM  See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc. Markit
Aug-30-17 08:02AM  See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc. Markit
03:00AM  Agios Pharmaceuticals Shows Rising Price Performance With Jump To 92 RS Rating Investor's Business Daily
Aug-28-17 07:53PM  Agios Pharmaceuticals, Inc. Value Analysis (NASDAQ:AGIO) : August 28, 2017 Capital Cube
Aug-18-17 09:45AM  Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AGIO-US : August 18, 2017 Capital Cube
Aug-14-17 08:05AM  See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc. Markit
Aug-11-17 07:01PM  Edited Transcript of AGIO earnings conference call or presentation 8-Aug-17 12:00pm GMT Thomson Reuters StreetEvents
Aug-10-17 08:04AM  IHS Markit Score Update: Drop in demand for ETFs holding Agios Pharmaceuticals Inc is a negative sign for its shares Markit
Aug-09-17 11:13AM  Agios (AGIO) Q2 Loss Wider than Expected, Revenues Up Y/Y Zacks
Aug-08-17 10:23PM  Agios Pharmaceuticals reports 2Q loss Associated Press
09:12AM  Agios (AGIO) Q2 Loss Wider than Expected; Sales Miss Zacks
07:01AM  Agios Reports Second Quarter 2017 Financial Results GlobeNewswire
Aug-07-17 02:50PM  4 Medical Product Stocks Likely to Top Q2 Earnings Estimates Zacks
09:34AM  Med-Product Stocks Aug 8 Earnings Roster: HSIC, AGIO & More Zacks
08:43AM  Is a Surprise Coming for Agios Pharmaceuticals (AGIO) This Earnings Season? Zacks
Aug-03-17 04:01PM  Agios to Present at the Canaccord Genuity 37th Annual Growth Conference Thursday, August 10, 2017 GlobeNewswire
08:36AM  Agios Pharmaceuticals (AGIO) Looks Good: Stock Adds 5.1% in Session Zacks
08:15AM  Celgene CEO: Precision medicine targeting metabolic drive... CNBC Videos
Aug-02-17 04:07PM  This Small Biotech Launched To A 9-Month High Today Here's Why Investor's Business Daily +5.10%
Aug-01-17 03:06PM  FDA approves leukemia treatment developed by Celgene, Agios Reuters
11:47AM  A small biotech behind a groundbreaking approach to tackling cancer just got its first drug approved Business Insider
11:30AM  FDA Grants Approval of IDHIFA®, the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation Business Wire
11:21AM  FDA approves leukemia treatment developed by Celgene, Agios Reuters
Jul-28-17 07:30AM  Agios to Webcast Conference Call of Second Quarter 2017 Financial Results on August 8, 2017 GlobeNewswire
Jul-27-17 11:37AM  Revlimid drives Celgene profit beat; raises EPS forecast Reuters
Jul-26-17 10:55AM  What's in Store for Agios Pharma (AGIO) in Q2 Earnings? Zacks
Jul-12-17 02:56PM  Newman Ferrara LLP Announces Corporate Governance Investigation of Agios Pharmaceuticals Inc. - AGIO Business Wire
Jun-27-17 11:38AM  Agios/Celgene's Leukemia Candidate Positive in Phase I/II Zacks -5.74%
Jun-26-17 04:10PM  Biotech Rally Stumbles As These Small Caps Pull Back Investor's Business Daily -7.57%
11:05AM  Agio Pharma Sinks on Midstage Trial 24/7 Wall St.
Jun-24-17 04:54PM  Agios Pharma Announces Updated Data from Fully Enrolled DRIVE PK Study Demonstrating AG-348's Potential as First Disease-modifying Treatment for Patients with PKR #EHA2017 Benzinga
08:05AM  New Data from Phase 1/2 Trial of Oral IDHIFA® (enasidenib) Demonstrate Durable Complete Responses in Patients with IDH2 Mutant Relapsed or Refractory AML GlobeNewswire
08:00AM  Agios Announces Updated Data from Fully Enrolled DRIVE PK Study Demonstrating AG-348s Potential as the First Disease-modifying Treatment for Patients with Pyruvate Kinase Deficiency GlobeNewswire
Jun-15-17 12:57PM  ETFs with exposure to Agios Pharmaceuticals, Inc. : June 15, 2017 Capital Cube
Jun-14-17 01:58PM  Agios Pharmaceuticals, Inc. Value Analysis (NASDAQ:AGIO) : June 14, 2017 Capital Cube
Jun-13-17 08:26AM  Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AGIO-US : June 13, 2017 Capital Cube
Jun-08-17 03:32AM  Agios (AGIO) Up 2.6% Since Earnings Report: Can It Continue? Zacks
Jun-07-17 10:07AM  Celgene and Agios Announce Data on Idhifa for Leukemia Zacks
Jun-06-17 12:26PM  Updated Data from Phase 1 Trial of Oral IDHIFA® (enasidenib) Demonstrate Complete Responses and Duration of Response in Patients with Relapsed or Refractory AML and an IDH2 Mutation Business Wire
Jun-05-17 01:48PM  Notes From ASCO 2017: Tesaro, Amgen, Others Report New Data Benzinga
Jun-03-17 09:00AM  Agios Presents Phase 1 Data from Dose-Escalation and Expansion Cohorts of AG-120 (Ivosidenib) in Patients with Previously Treated IDH1 Mutant Positive Cholangiocarcinoma GlobeNewswire
May-31-17 04:05PM  Agios Appoints David Scadden, M.D., to the Board of Directors GlobeNewswire
May-22-17 01:19PM  ETFs with exposure to Agios Pharmaceuticals, Inc. : May 22, 2017 Capital Cube
May-21-17 01:00PM  A small Boston biotech is at the heart of a groundbreaking approach to tackling cancer Business Insider
May-18-17 07:08AM  Agios to Present Updated Clinical Data from PKR Activator AG-348 at EHA GlobeNewswire
May-17-17 05:29PM  Agios to Present New Clinical Data from its IDH Programs at ASCO GlobeNewswire -5.37%
05:02PM  Celgene, Agios Update Blood Cancer Drug Study Results in ASCO '17 Abstract TheStreet.com
May-15-17 08:20AM  Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AGIO-US : May 15, 2017 Capital Cube
May-12-17 11:15AM  Edited Transcript of AGIO earnings conference call or presentation 4-May-17 12:00pm GMT Thomson Reuters StreetEvents
May-08-17 04:06PM  ETFs with exposure to Agios Pharmaceuticals, Inc. : May 8, 2017 Capital Cube
May-05-17 11:10AM  Agios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017 Capital Cube +5.73%
10:04AM  Agios (AGIO) Q1 Loss Narrower than Expected, Indhifa in Focus Zacks
May-04-17 09:14AM  Agios (AGIO) Q1 Loss Narrower than Expected; Sales Down Y/Y Zacks
08:01AM  Agios Pharmaceuticals reports 1Q loss Associated Press
07:05AM  Investor Network: Agios Pharmaceuticals, Inc. to Host Earnings Call Accesswire
07:01AM  Agios Reports First Quarter 2017 Financial Results GlobeNewswire
May-03-17 07:18AM  3 Debt-Free Clinical-Stage Biotech Stocks That Are Swimming in Cash Motley Fool
05:51AM  [$$] Four Small Biotechs See Bullish April Stock Buys Barrons.com
May-01-17 10:21AM  Agios Pharmaceuticals (AGIO) Q1 Earnings: What's in Store? Zacks
Apr-28-17 04:01PM  Agios Announces Closing of Over-Allotment Option in Public Offering GlobeNewswire
Apr-27-17 07:30AM  Agios and Aurigene Enter into Exclusive License Agreement for Novel Small Molecules for Cancer Metabolism Target GlobeNewswire
07:25AM  Agios to Webcast Conference Call of First Quarter 2017 Financial Results on May 4, 2017 GlobeNewswire
Apr-26-17 08:04AM  The 1 Stock I'd Buy Right Now Motley Fool
07:01AM  Agios Announces Exercise of Over-Allotment Option in Public Offering GlobeNewswire
Apr-24-17 04:01PM  Agios Announces Closing of Public Offering GlobeNewswire
Apr-20-17 02:47PM  Agios Pharmaceuticals, Inc. Value Analysis (NASDAQ:AGIO) : April 20, 2017 Capital Cube
Apr-19-17 08:30AM  Agios Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AGIO-US : April 19, 2017 Capital Cube
Apr-18-17 08:34PM  Agios Announces Pricing of $250 Million Public Offering of Common Stock GlobeNewswire -9.28%
Apr-17-17 04:01PM  Agios Announces Proposed Offering of Common Stock GlobeNewswire
08:42AM  3 Cancer Drug Stocks That Could Make You Rich Motley Fool
Mar-30-17 07:30AM  Agios to Present at the 16th Annual Needham Healthcare Conference on Tuesday April 4, 2017 GlobeNewswire
Mar-21-17 12:49PM  4 Health Care Charts Signaling Buys: Pfizer, Amgen Included -5.36%
Mar-20-17 04:32AM  Why Is Agios (AGIO) Up 8.5% Since the Last Earnings Report? Zacks
Mar-13-17 07:49AM  AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:30AM  Agios Announces MTAP Pathway Research Program as Development Program and Development Candidate Under Master Research and Collaboration Agreement with Celgene GlobeNewswire
Mar-12-17 02:40PM  Biotechs Among 5 Stocks Setting Up for Major Breakouts TheStreet.com
02:40PM  Biotechs Among 5 Stocks Setting Up for Major Breakouts
Mar-07-17 11:17AM  These stocks are getting whacked after the GOP unveils its Obamacare replacement Yahoo Finance
Mar-01-17 03:15PM  Agios CEO touts path from 'a blank piece of paper' to cusp of drug approval at bizjournals.com +6.81%
03:15PM  Agios CEO touts path from 'a blank piece of paper' to cusp of drug approval American City Business Journals
07:30AM  FDA Accepts New Drug Application and Grants Priority Review for Enasidenib in Relapsed or Refractory AML with an IDH2 Mutation Business Wire
Feb-28-17 07:30AM  Agios to Present at the Cowen and Company 37th Annual Health Care Conference on Monday, March 6, 2017 GlobeNewswire
Feb-22-17 01:04PM  AGIOS PHARMACEUTICALS INC Financials
Feb-21-17 10:59AM  Agios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: Q4, 2016 By the Numbers : February 21, 2017 Capital Cube -6.82%
10:59AM  Agios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: Q4, 2016 By the Numbers : February 21, 2017
Feb-17-17 12:30PM  Agios Pharmaceuticals 4Q Loss $1.48 Per Share at Investopedia +8.55%
12:20PM  Agios Pharmaceuticals, Inc. :AGIO-US: Earnings Analysis: 2016 By the Numbers : February 17, 2017
09:27AM  Agios Pharma (AGIO) Q4 Loss Narrower than Expected; Stock Up
Feb-16-17 11:34AM  Edited Transcript of AGIO earnings conference call or presentation 16-Feb-17 1:00pm GMT +8.04%
08:53AM  Agios (AGIO) Q4 Loss Narrower than Expected; Revenues Up Y/Y
08:00AM  Agios Pharmaceuticals Inc Earnings Call scheduled for 8:00 am ET today
07:21AM  AGIOS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
07:16AM  Agios Pharmaceuticals reports 4Q loss
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. The company is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase 1 clinical trials for the treatment of hematologic malignancies and solid tumors; and AG-348, a small molecule potent activator that is in Phase 2 clinical trial for the treatment of pyruvate kinase deficiency. It has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cantley Lewis Clayton Jr.DirectorSep 14Sale65.711,00065,71085,434Sep 15 04:54 PM
Cantley Lewis Clayton Jr.DirectorSep 14Sale65.711,00065,71085,394Sep 15 04:54 PM
Cantley Lewis Clayton Jr.DirectorSep 13Sale65.471,00065,47086,434Sep 15 04:54 PM
Cantley Lewis Clayton Jr.DirectorSep 13Sale65.471,00065,47086,394Sep 15 04:54 PM
Bowden ChristopherChief Medical OfficerSep 11Option Exercise35.166,000210,9606,881Sep 13 04:38 PM
Biller ScottChief Scientific OfficerSep 11Sale65.0015,000975,00010,470Sep 13 04:37 PM
Bowden ChristopherChief Medical OfficerSep 11Sale65.006,000390,000881Sep 13 04:38 PM
Schenkein David PChief Executive OfficerSep 01Option Exercise0.306,0001,8156,000Sep 05 05:22 PM
Biller ScottChief Scientific OfficerSep 01Option Exercise9.052,14619,4218,410Sep 05 05:25 PM
Schenkein David PChief Executive OfficerSep 01Sale62.206,000373,2000Sep 05 05:22 PM
Biller ScottChief Scientific OfficerSep 01Sale61.992,146133,0316,264Sep 05 05:25 PM
Cantley Lewis Clayton Jr.DirectorAug 23Sale57.081,00057,08087,434Aug 24 04:13 PM
Cantley Lewis Clayton Jr.DirectorAug 23Sale57.081,00057,08087,394Aug 24 04:13 PM
Cantley Lewis Clayton Jr.DirectorAug 22Sale56.621,00056,62088,434Aug 24 04:13 PM
Cantley Lewis Clayton Jr.DirectorAug 22Sale56.621,00056,62088,394Aug 24 04:13 PM
Schenkein David PChief Executive OfficerAug 02Option Exercise0.3024,0007,26024,000Aug 03 05:26 PM
Biller ScottChief Scientific OfficerAug 02Sale60.0621,0001,261,26025,470Aug 03 05:29 PM
Schenkein David PChief Executive OfficerAug 02Sale60.5524,0001,453,2000Aug 03 05:26 PM
Schenkein David PChief Executive OfficerAug 01Option Exercise0.303,0009083,000Aug 03 05:26 PM
Biller ScottChief Scientific OfficerAug 01Option Exercise9.052,14619,4218,410Aug 03 05:29 PM
Schenkein David PChief Executive OfficerAug 01Sale55.123,000165,3600Aug 03 05:26 PM
Biller ScottChief Scientific OfficerAug 01Sale55.052,146118,1376,264Aug 03 05:29 PM
Cantley Lewis Clayton Jr.DirectorJul 20Sale57.131,00057,12585,237Jul 21 04:05 PM
Cantley Lewis Clayton Jr.DirectorJul 20Sale57.131,00057,12585,197Jul 21 04:05 PM
Cantley Lewis Clayton Jr.DirectorJul 19Sale56.143,500196,50586,237Jul 21 04:05 PM
Cantley Lewis Clayton Jr.DirectorJul 19Sale56.143,500196,50586,197Jul 21 04:05 PM
Biller ScottChief Scientific OfficerJul 07Option Exercise9.052,14619,4218,410Jul 11 04:07 PM
Biller ScottChief Scientific OfficerJul 07Sale55.002,146118,0306,264Jul 11 04:07 PM
Schenkein David PChief Executive OfficerJul 03Option Exercise0.303,0009083,000Jul 06 04:31 PM
Schenkein David PChief Executive OfficerJul 03Sale51.183,000153,5400Jul 06 04:31 PM
Biller ScottChief Scientific OfficerJun 23Option Exercise0.473,0001,4036,264Jun 27 04:33 PM
Biller ScottChief Scientific OfficerJun 21Option Exercise5.527,29240,2454,556Jun 23 04:08 PM
Biller ScottChief Scientific OfficerJun 21Sale55.004,292236,060264Jun 23 04:08 PM
Cantley Lewis Clayton Jr.DirectorJun 14Sale51.0950025,54589,737Jun 15 05:02 PM
Cantley Lewis Clayton Jr.DirectorJun 14Sale51.0950025,54589,697Jun 15 05:02 PM
Cantley Lewis Clayton Jr.DirectorJun 13Sale50.6450025,32090,237Jun 15 05:02 PM
Cantley Lewis Clayton Jr.DirectorJun 13Sale50.6450025,32090,197Jun 15 05:02 PM
Schenkein David PChief Executive OfficerJun 07Option Exercise0.301,9005751,900Jun 08 04:06 PM
Schenkein David PChief Executive OfficerJun 07Sale50.021,90095,0380Jun 08 04:06 PM
Schenkein David PChief Executive OfficerJun 06Option Exercise0.301,1003331,100Jun 08 04:06 PM
Schenkein David PChief Executive OfficerJun 06Sale50.021,10055,0220Jun 08 04:06 PM
Cantley Lewis Clayton Jr.DirectorMay 25Sale46.9250923,88290,737May 25 07:03 PM
Cantley Lewis Clayton Jr.DirectorMay 25Sale46.9250923,88290,697May 25 07:03 PM
Cantley Lewis Clayton Jr.DirectorMay 24Sale47.2750924,06091,246May 25 07:03 PM
Cantley Lewis Clayton Jr.DirectorMay 24Sale47.2750924,06091,206May 25 07:03 PM
Schenkein David PChief Executive OfficerMay 01Option Exercise0.303,0009083,000May 02 04:03 PM
Schenkein David PChief Executive OfficerMay 01Sale50.063,000150,1800May 02 04:03 PM
Celgene European Investment Co10% OwnerApr 24Buy49.50624,57530,916,4631,856,353Apr 24 04:34 PM
Cantley Lewis Clayton Jr.DirectorApr 18Sale50.9250925,91891,755Apr 19 05:16 PM
Cantley Lewis Clayton Jr.DirectorApr 18Sale50.9250925,91891,715Apr 19 05:16 PM
Cantley Lewis Clayton Jr.DirectorApr 17Sale55.242,036112,45892,264Apr 19 05:16 PM
Cantley Lewis Clayton Jr.DirectorApr 17Sale55.242,036112,45892,224Apr 19 05:16 PM
Schenkein David PChief Executive OfficerApr 03Option Exercise0.303,0009083,000Apr 05 04:04 PM
Biller ScottChief Scientific OfficerApr 03Option Exercise9.052,14619,42117,880Apr 05 04:05 PM
Schenkein David PChief Executive OfficerApr 03Sale58.623,000175,8600Apr 05 04:04 PM
Biller ScottChief Scientific OfficerApr 03Sale58.032,146124,53215,734Apr 05 04:05 PM
Cantley Lewis Clayton Jr.DirectorMar 23Sale53.9150927,44094,300Mar 24 04:20 PM
Cantley Lewis Clayton Jr.DirectorMar 23Sale53.9150927,44094,260Mar 24 04:20 PM
Cantley Lewis Clayton Jr.DirectorMar 22Sale52.3150926,62694,809Mar 24 04:20 PM
Cantley Lewis Clayton Jr.DirectorMar 22Sale52.3150926,62694,769Mar 24 04:20 PM
Biller ScottChief Scientific OfficerMar 20Option Exercise8.386,43853,93021,403Mar 22 05:10 PM
Biller ScottChief Scientific OfficerMar 20Sale55.006,438354,09015,470Mar 22 05:10 PM
NELSEN ROBERTDirectorMar 06Sale49.43401,9770Mar 07 04:35 PM
NELSEN ROBERTDirectorMar 03Sale50.8540,5592,062,23240Mar 07 04:35 PM
Schenkein David PChief Executive OfficerMar 01Option Exercise0.303,0009083,000Mar 03 04:36 PM
Schenkein David PChief Executive OfficerMar 01Sale50.473,000151,4100Mar 03 04:36 PM
NELSEN ROBERTDirectorFeb 28Sale49.7747,8592,381,81540,599Mar 01 05:37 PM
NELSEN ROBERTDirectorFeb 27Sale49.26195,2239,616,08088,458Mar 01 05:37 PM
NELSEN ROBERTDirectorFeb 23Sale47.9050,9962,442,461283,681Feb 23 07:20 PM
NELSEN ROBERTDirectorFeb 22Sale49.9147,9382,392,754334,677Feb 23 07:20 PM
NELSEN ROBERTDirectorFeb 21Sale50.7336,4301,848,249382,615Feb 23 07:20 PM
Schenkein David PChief Executive OfficerFeb 16Option Exercise0.306,0001,8156,000Feb 17 04:36 PM
Schenkein David PChief Executive OfficerFeb 16Sale50.016,000300,0600Feb 17 04:36 PM
Biller ScottChief Scientific OfficerNov 14Option Exercise12.2627,500337,03775,770Nov 16 04:52 PM
Biller ScottChief Scientific OfficerNov 14Sale65.005,000325,0006,000Nov 16 04:52 PM
Biller ScottChief Scientific OfficerNov 14Sale65.0027,5001,787,50048,270Nov 16 04:52 PM
Biller ScottChief Scientific OfficerNov 10Sale60.002,128127,68011,000Nov 14 06:07 PM
Biller ScottChief Scientific OfficerNov 09Sale60.002,872172,32013,128Nov 14 06:07 PM
Cantley Lewis Clayton Jr.DirectorOct 27Sale48.9762530,606107,818Oct 28 04:03 PM
Cantley Lewis Clayton Jr.DirectorOct 27Sale48.9762730,704107,778Oct 28 04:03 PM
Cantley Lewis Clayton Jr.DirectorOct 26Sale48.9162530,569108,443Oct 28 04:03 PM
Cantley Lewis Clayton Jr.DirectorOct 26Sale48.9162730,667108,405Oct 28 04:03 PM
Biller ScottChief Scientific OfficerOct 05Sale55.005,000275,00016,000Oct 06 04:14 PM
Cantley Lewis Clayton Jr.DirectorSep 28Sale54.0062533,750109,068Sep 28 05:29 PM
Cantley Lewis Clayton Jr.DirectorSep 28Sale54.0062733,858109,032Sep 28 05:29 PM
Cantley Lewis Clayton Jr.DirectorSep 27Sale54.1562533,844109,693Sep 28 05:29 PM
Cantley Lewis Clayton Jr.DirectorSep 27Sale54.1562733,952109,659Sep 28 05:29 PM
Biller ScottChief Scientific OfficerSep 20Sale50.005,000250,00021,000Sep 22 04:40 PM